{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:13:11Z","timestamp":1760044391346,"version":"3.40.4"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jctube.2025.100514","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:59:11Z","timestamp":1738371551000},"page":"100514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Challenges in achieving the guideline-recommended amikacin level for Mycobacterium avium complex pulmonary disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Takuya","family":"Akutsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Tone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Airi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Inaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Gochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2025.100514_b0005","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease","volume":"22","author":"Namkoong","year":"2016","journal-title":"Japan Emerg Infect Dis"},{"key":"10.1016\/j.jctube.2025.100514_b0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jctube.2025.100514_b0015","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2025.100514_b0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/resp.12676","article-title":"Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease","volume":"21","author":"Ellender","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.jctube.2025.100514_b0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.rmed.2010.12.012","article-title":"Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs","volume":"105","author":"Lyu","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.jctube.2025.100514_b0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/cid\/ciac784","article-title":"Less is more? Antibiotic treatment duration in Pseudomonas aeruginosa ventilator-associated pneumonia","volume":"76","author":"Albin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2025.100514_b0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40360-019-0302-1","article-title":"Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto","volume":"20","author":"Aznar","year":"2019","journal-title":"Canada BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jctube.2025.100514_b0040","doi-asserted-by":"crossref","unstructured":"C.S. Haworth, J. Banks, T. Capstick, A.J. Fisher, T. Gorsuch, I.F. Laurenson, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017;72:ii1-ii64.","DOI":"10.1136\/thoraxjnl-2017-210927"},{"year":"2003","series-title":"M24-A: susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes; approved standard","author":"Clsi","key":"10.1016\/j.jctube.2025.100514_b0045"},{"issue":"24","key":"10.1016\/j.jctube.2025.100514_b0050","first-page":"00397","article-title":"The association between sputum culture conversion and mortality in cavitary Mycobacterium avium complex pulmonary disease","volume":"S0012\u20133692","author":"Lee","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jctube.2025.100514_b0055","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579425000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579425000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:47:59Z","timestamp":1746118079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579425000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":11,"alternative-id":["S2405579425000051"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2025.100514","relation":{},"ISSN":["2405-5794"],"issn-type":[{"type":"print","value":"2405-5794"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in achieving the guideline-recommended amikacin level for Mycobacterium avium complex pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2025.100514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100514"}}